Mrinmoy Chakrabarti, PhD

Associate
Norton Rose Fulbright US LLP
mrinmoy.chakrabarti@nortonrosefulbright.com
Mrinmoy
Chakrabarti
Mrinmoy Chakrabarti, PhD
Austin
Suite 1100
98 San Jacinto Boulevard
Austin
Texas
78701-4255
United States
+1 512 536 3076
San Antonio
Suite 1800
Frost Tower 111 W. Houston Street
San Antonio
Texas
78205
United States
+1 210 224 5575

Mrinmoy Chakrabarti uses his patent prosecution, scientific research and technology transfer experience to develop practical strategies for protecting and leveraging clients’ intellectual property. He has experience prosecuting patent applications in the chemical, biological and medical device fields. His practice experience includes patent drafting and prosecution, portfolio management, patentability and freedom-to-operate analysis, infringement analysis, due diligence and patent landscape assessments.

Prior to his patent practice, Mrinmoy accumulated deep research experience focused on the structure-function relationships of metalloproteins and cellular metal homeostasis. His experience included synthesizing functional and structural mimics of metalloproteins, and developing biophysical, spectroscopic methods to study biomolecules and biological pathways. This scientific background provides him with a practical understanding of complex chemical and biological technologies and helps him translate technical innovation into effective intellectual property strategies. Mrinmoy also has technology transfer experience, and is well versed with steps required to take an invention from laboratory to the market.

Representative experience

  • Small-molecule therapeutics including inhibitors, agonists and antagonists.
  • Large‑molecule therapeutic platforms, including gene therapy programs involving AAV capsid engineering, nanoparticle based delivery systems, payload delivery and mRNA‑based therapeutics for cancer and infectious disease vaccines; protein and peptide‑based therapeutics, antibodies; gene‑editing applications using CRISPR/Cas systems; CAR‑ and T‑cell‑related technologies.
  • Biologic modalities including peptides, antibodies, antibody–drug conjugates, cytokines, mRNA, siRNA, shRNA and miRNA.
  • Cell therapy technologies, including fibroblast-based approaches; microbiome and biotherapeutic technologies, including microbiome-modulating agents and bacteriophage cocktails; pharmaceutical formulations, including extended-release and delayed-release formulations.
  • Diagnostic technologies involving biomarkers, detection of volatile organic compounds and patient classification based on gene-expression profiles, including predicting whether a patient will respond to a drug; patient-classification technologies based on responses to defined sets of questions.
  • Polymer chemistry, catalysis and oil and gas technology.

Education

  • JD, University of Texas, 2026

    • Environmental law Clinic
    • Staff editor, Texas Intellectual Property Law Journal
  • PhD, Chemistry, Carnegie Mellon University, 2010

  • MS, Chemistry, Indian Institute of Technology, Kanpur, 2005

Admissions

  • Texas State Bar
  • US Patent and Trademark Agent

Languages

  • Bengali

Publications

  • Author, “The catalytic mechanism for aerobic formation of methane by bacteria,” Nature, April 24, 2013
  • Author, “A Family of Diiron Monooxygenases Catalyzing Amino Acid Beta Hydroxylation in Antibiotic Biosynthesis,” Proceedings of National Academy of Sciences, August 16, 2010
  • Author, “Trapping and Spectroscopic Characterization of a FeIII-superoxo Intermediate from a Nonheme Mononuclear Iron Containing Enzyme,” Proceedings of National Academy of Sciences, September 13, 2010
Bio